Copy number variations of the IL-22 gene are associated with ankylosing spondylitis: A case-control study in Chinese Han population

IL-22 provides a new insight into the mechanisms of autoimmunity, and copy number variations (CNVs) are associated with autoimmune diseases. This study aims to explore the association of IL-22 gene CNVs with ankylosing spondylitis (AS) susceptibility. The copy numbers of IL-22 gene (2 fragments: IL-22_1, IL-22_2) were examined by AccuCopy? methods in a cohort of 649 AS patients and 628 controls. Association of IL-22 CNVs and AS susceptibility was analyzed, and AS risk was estimated by Odds Ratio (ORs) and 95% confidence intervals (CIs), and the Benjamini-Hochberg method was applied to regulate the false discovery rate (FDR). We found one copy of IL-22 gene was significantly associated with AS [OR = 0.345, 95%CI (0.144, 0.827), P = 0.013, P_FDR = 0.026] in the IL-22_2 fragment, and this association still exist after adjustment of age and sex [OR = 0.344, 95%CI (0.143, 0.825), P = 0.017, P_FDR = 0.034]. In the stratification analysis by gender, the statistical difference was detected in males in the IL-22_2 fragment [OR = 0.306, 95%CI (0.121, 0.778), P = 0.009, P_FDR = 0.018; adjusted OR = 0.306, 95%CI (0.120, 0.777), P = 0.013, P_FDR = 0.026]. We suggest that IL-22 CNVs are associated with AS and that lower copy number might be a protective factor for AS, especially in male patients.     

抗中性粒细胞胞质抗体相关性血管炎治疗进展

随着大量针对抗中性粒细胞胞浆抗体(ANCA)相关性血管炎(AAV)临床试验的开展,对其治疗逐渐达成共识:目前AAV的治疗主要分为诱导缓解,维持缓解和复发治疗,环磷酰胺和糖皮质激素仍然是主要的治疗手段,甲氨蝶呤、霉酚酸酯、美罗华、硫唑嘌呤、血浆置换等的治疗价值也得到了进一步的肯定和定位,AAV治疗更趋于个体化。最近,基于对AAV发病机制研究的不断深入,以淋巴细胞和细胞因子为靶向的新的治疗手段,有望进一步改善患者愈后。     

85例急性重型胰腺炎死亡原因分析

目的：探讨影响胰腺炎病死率的因素。方法：８５例急性重型胰腺炎（ＡＳＰ）死亡患者按时间划分为３个阶段：１９８４年～１９９０年为Ⅰ阶段，１９９１年～１９９３年为Ⅱ阶段，１９９４年～１９９７年为Ⅲ阶段，分析不同时期ＡＳＰ的死亡原因。结果：Ⅰ、Ⅱ、Ⅲ阶段手术率逐渐降低，分别为７７．５９％，５４．５５％和２９．２９％（Ｐ均＜０．００５），手术组病死率分别为４７．７８％，２０．３７％和１５．５２％（Ｐ均＜０．００５）；３阶段非手术组病死率分别为１５．３８％，１３．３３％和８．５７％。Ⅰ和Ⅲ阶段非手术组病死率低于手术组（Ｐ均＜０．０５），且Ⅲ阶段合计死亡２１例，病死率为１０．６１％，低于Ⅰ阶段病死率（Ｐ＜０．０５）。结论：早期手术、误诊误治、并发症处理不及时、营养不良与死亡密切相关，休克和急性呼吸窘迫综合征（ＡＲＤＳ）是早期死亡的主要原因，胰周脓肿和多器官衰竭（ＭＯＦ）是后期死亡的主要原因，严格掌握手术指征非常重要。     

Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis

The objective of the study is to quantitatively assess the risk of serious infections in patients with axial spondyloarthritis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) treated by biologics enrolled in randomized controlled trials (RCTs). A systematic literature searches of MEDLINE (via PubMed), EMBASE, the Cochrane Library and abstracts archives of the annual scientific meetings of both the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) was conducted through October 2015. The RCTs that compared the safety of any biologics treatment for AS or nr-axSpA with placebo and/or non-steroidal anti-inflammatory drugs (NSAIDs) and/or conventional disease modifying antirheumatic drugs (DMARDs) with a minimum of 12 weeks of follow-up were selected independently by 2 reviewers. Twenty-five RCTs with data from 2403 patients were analyzed in the analysis. Patients included active AS in 21 studies and nr-axSpA in 4 studies were treated by 5 TNF inhibitors (adalimumab, certolizumab, etanercept, golimumab and infliximab) and 3 non-TNF inhibitors (sarilumab, tocilizumab, secukinumab). The risk of serious infections has no difference and numerically was only slightly increased in patients with AS and nr-axSpA treated by biologics compared with controls (OR?=?1.42; 95%CI 0.58–3.47). Stratified analysis yielded the pooled risk differences (RDs) of 0.00 (95%CI, ??0.01 to 0.01), 0.01 (95%CI ??0.01 to 0.03), ??0.00 (95%CI ?0.01 to 0.01), 0.00 (95%CI ??0.02 to 0.02), 0.01 (95%CI ?0.01 to 0.03) and 0.01 (95%CI ?0.02 to 0.04) for adalimumab, certolizumab, etanercept, golimumab, infliximab and non-TNF inhibitors respectively. There are also no significant effect of biologics on serious infections was observed compared with controls in patients with AS (p?=?0.29) and nr-axSpA (p?=?0.89). The use of biologics among patients with AS and nr-axSpA included in RCTs was not significantly associated with an increased risk of serious infections compared with placebo or NSAIDs or DMARDs.     

部分脾动脉栓塞术治疗重症急性胰腺炎合并胰源性门静脉高压症的临床分析

背景与目的：重症急性胰腺炎（SAP）患者病情危重、进展迅速,具有较多的并发症,其中,胰源性门静脉高压症（PPH）是一种局限性区域性的门静脉高压症。部分患者PPH代偿较好,无明显的临床症状,仅在检查时发现存在脾大等情况,只需内科保守治疗并定期随访即可;对于出现PPH相关症状的患者,目前推荐行脾脏切除术。然而SAP合并PPH的患者,其全身一般情况较差,炎性水肿和腹腔感染较重,行脾脏切除术有加重感染和出血的风险,针对该类患者的治疗方法,目前国内外缺少一定的推荐及共识。因此,本研究主要探讨部分脾动脉栓塞术（PSE）治疗有症状的SAP合并PPH患者的临床效果以及处理的指征、时机和流程方法。方法：回顾性总结2014年1月—2021年12月南京大学医学院附属金陵医院重症医学科收治的15例SAP合并PPH患者的临床资料,分析患者采用PSE治疗PPH的临床诊疗经过及预后,观察患者PPH临床症状缓解情况、实验室血常规检验结果、影像学检查结果、术后并发症情况、是否有PPH症状再发。术后3 d与1、3、6个月进行影像学评估,术前及术后1年进行SF-36生活质量量表评分。结果：15例患者入院后均给予常规补液、抗...     

全髋关节置换术围手术期深静脉血栓形成防治的临床研究

目的 探讨全髋关节置换术围手术期深静脉血栓形成（DVT）的治疗措施.方法 回顾性分析300例行人工全髋关节置换术患者的临床资料.所有患者入院时均常规检测凝血功能,术后第1,3,5天监测D-二聚体（D-D）水平.疑似DVT患者,行下肢彩色多普勒超声检查,诊断不明确时行静脉造影.全部患者均接受物理治疗和预防性抗凝治疗.结果 术前共诊断DVT20例（30侧肢体）,中心型7例,周围型13例.所有患者进行术前抗凝治疗后,非DVT患者D-D水平呈逐渐下降趋势;DVT患者第1天和第3天D-D仍维持在高水平状态,平均D-D分别为6500,6800 μg/L.其他280例全髋关节置换术病例中共发现40例DVT.其中周围型DVT患者术后继续抗凝治疗6个月,中心型或混合型DVT患者骨科手术后放置临时腔静脉滤器,所有患者围手术期均未出现严重并发症.结论 全髋关节置换术患者术前需要充分监测评估,术后需早期进行功能锻炼,并联合抗凝治疗预防DVT.     

Comparison of the efficacy and safety of the adalimumab biosimilar TQ-Z2301 and adalimumab for the treatment of Chinese patients with active ankylosing spondylitis: a multi-center,randomized, double-blind,phase III clinical trial

Clinical Rheumatology - To assess the clinical equivalence of TQ-Z2301, a biosimilar of adalimumab, to the reference adalimumab in the treatment of Chinese patients with active ankylosing...     

温控型胰岛素液体缓释肛门栓体外释放研究

目的 用高效液相色谱法建立温控型胰岛素液体缓释肛门栓中胰岛素含量测定的方法,以察温控型胰岛素液体缓释肛门栓的体外释放特性.方法 色谱柱：Welch ultimate C18（4.6 mm＆#215;250 mm,5μm）;流动相：0.2 mol/L硫酸盐缓冲液-乙腈（74∶26,乙醇胺调pH到2.3）;检测波长：214 nm;柱温：40℃;流速：1 ml/min,对胰岛素含量进行测定.采用无膜释放模型、牛肠黏膜释放模型、羊肠黏膜释放模型,以胰岛素原料药为模型药物;考察温控型胰岛素液体缓释肛门栓的体外释药机制.结果 温控型胰岛素液体缓释肛门栓在1.0 ～40.0 U/ml范围内线性关系良好（r=0.999 1）,平均回收率99.35％,RSD为0.79％;无膜释放：Q=0.4954t-2.6118（r=0.9977）;牛肠黏膜释放：（1-Q） 1/3 =0.001 6t ＋2.927 4（r=0.975 5）羊肠黏膜释放：lnQ=0.878 3lnt-4.931 1（r=0.9705）.结论 此方法简便,重复性好、专属性强、结果准确、可靠,适用于该制剂中胰岛素含量的测定.可考察温控型胰岛素液体缓释肛门栓机制.     

LncRNA UCA1对肺癌细胞放射敏感性影响及机制研究

目的 研究长链非编码RNA (LncRNA) UCA1对肺癌细胞增殖、凋亡及放射敏感性影响及其机制。方法 运用qRT-PCR法检测肺癌细胞A549、H1299和人正常肺细胞HBE中UCA1、miR-513a-5p表达。将si-con组(转染si-con)、si-UCA1组(转染si-UCA1)、miR-513a-5p组(转染miR-513a-5p mimics)、miR-NC组(转染miR-NC)、IR+si-con组(转染si-con+照射)、IR+si-UCA1组(转染miR-NC+照射)、IR+miR-513a-5p组(转染miR-513a-5p mimics+照射)、IR+miR-NC组(转染miR-NC+照射)、IR+si-UCA1+anti-miR-513a-5p组(共转染si-UCA1和anti-miR-513a-5p+照射)均用脂质体法转染至A549、H1299细胞,然后部分组进行4Gy照射。MTT法检测各组细胞增殖,克隆形成实验检测细胞增敏比,流式细胞术检测各组细胞凋亡,双荧光素没报告基因检测实验检测各组细胞的荧光活性。结果 与HBE细胞相比,A549、H1299细胞中UCA1表达显著升高(P<0.05),miR-513a-5p表达显著降低(P<0.05)。抑制UCA1、过表达miR-513a-5p均可明显抑制A549、H1299细胞增殖、促进凋亡、提高放射敏感性(放射增敏比为1.897、2.146和1.615、1.872)。miR-513a-5p可抑制野生型UCA1细胞的荧光活性,且UCA1可负向调控miR-513a-5p的表达。抑制miR-513a-5p可逆转抑制UCA1对细胞的放射敏感性的增强作用。结论 抑制LncRNA UCA1可增强放射对肺癌细胞敏感性,其机制可能与靶向抑制miR-513a-5p有关。     

LncRNA MEG3靶向miR-181a-5p调控宫颈癌细胞放射敏感性

目的 研究LncRNA MEG3对宫颈癌细胞放射敏感性的影响,并探讨其作用机制。方法 运用qRT-PCR法检测放射抗性和放射敏感性宫颈癌细胞中LncRNA MEG3的表达;将过表达对照组(转染pcDNA 3.1)、过表达LncRNA MEG3组(转染pcDNA 3.1-LncRNA MEG3)、抑制miR-NC组(转染anti-miR-NC)、抑制miR-181a-5p组(转染anti-miR-181a-5p)、过表达LncRNA MEG3+过表达miR-NC组(共转染pcDNA 3.1-LncRNA MEG3和anti-miR-NC)、过表达LncRNA MEG3+过表达miR-181a-5p组(共转染pcDNA 3.1-LncRNA MEG3和anti-miR-181a-5p),均用脂质体法转染至SiHa细胞;克隆形成实验检测细胞的存活分数;流式细胞术检测细胞的凋亡率;双荧光素酶报告基因检测实验检测细胞的荧光活性;Western blot检测细胞中PTEN、p-Akt、Akt的蛋白表达。结果 与放射敏感组相比,放射抗性宫颈癌组织中LncRNA MEG3的表达明显降低(P<0.05),其表达量与宫颈癌细胞的放射敏感性呈正相关;过表达LncRNA MEG3、抑制miR-181a-5p均可显著增强宫颈癌细胞SiHa放射敏感性,促进凋亡(P<0.05);野生型LncRNA MEG3细胞的荧光活性受miR-181a-5p的抑制。过表达miR-181a-5p逆转了LncRNA MEG3对宫颈癌细胞放射增敏和促凋亡作用及对PTEN/Akt信号通路的调控。结论 长链非编码RNA LncRNA MEG3可增强宫颈癌细胞放射敏感性,其机制可能与靶向miR-181a-5p调控PTEN/Akt 信号通路有关,可为提高宫颈癌的预后提供新方向。